Skip to main content

Table 4 INR monitoring during the 1-year follow-up

From: Vasodilator-stimulated phosphoprotein-guided Clopidogrel maintenance therapy reduces cardiovascular events in atrial fibrillation patients requiring anticoagulation therapy and scheduled for percutaneous coronary intervention: a prospective cohort study

Categories

1 mo

3 mo

6 mo

9 mo

12 mo

P-value

VASP-guided group

1.8 ± 0.3

2.1 ± 0.5

1.9 ± 0.7

2.0 ± 0.2

2.2 ± 0.4

0.33

Control group

1.7 ± 0.9

2.0 ± 0.3

2.1 ± 0.5

1.9 ± 0.6

2.1 ± 0.2

0.48

CHA2DS2-VASc Score = 1

2.0 ± 0.2

1.7 ± 0.4

2.2 ± 0.9

2.0 ± 0.8

2.1 ± 0.7

0.56

CHA2DS2-VASc Score ≥ 2

1.9 ± 0.3

1.6 ± 0.6

2.3 ± 0.5

2.6 ± 0.9

2.5 ± 0.8

< 0.05

HAS-BLED Score < 2

1.6 ± 0.5

1.8 ± 0.4

2.0 ± 0.6

2.1 ± 0.4

2.2 ± 0.7

0.14

HAS-BLED Score ≥ 3

1.7 ± 0.2

1.9 ± 0.5

2.1 ± 0.6

2.2 ± 0.4

2.1 ± 0.8

0.35

  1. P-value: 1 month vs. 12 months